Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bio-Techne

50.13
+0.63001.27%
Post-market: 50.130.00000.00%19:48 EDT
Volume:2.16M
Turnover:108.36M
Market Cap:7.86B
PE:60.40
High:50.42
Open:49.58
Low:49.05
Close:49.50
Loading ...

Bio-Techne beats Q2 earnings estimates on improving demand for biotech products

Reuters
·
05 Feb

Bio-Techne Corp Q2 FY2025 Earnings: Revenue Hits $297M, Adjusted EPS at $0.42, Surpassing Estimates

GuruFocus
·
05 Feb

Stock Track | Bio-Techne Soars 5.83% in Pre-Market on Strong Q2 Earnings Beat

Stock Track
·
05 Feb

Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars

StockStory
·
05 Feb

Bio-Techne's Fiscal Q2 Adjusted Earnings, Net Sales Rise

MT Newswires Live
·
05 Feb

Earnings Flash (TECH) Bio-Techne Posts Fiscal Q2 Net Sales $297 Million, vs. FactSet Est of $285.8 Million

MT Newswires Live
·
05 Feb

Earnings Flash (TECH) Bio-Techne Posts Fiscal Q2 Adjusted EPS $0.42, vs. FactSet Est of $0.39

MT Newswires Live
·
05 Feb

Bio-Techne Shares up 5.8% Premarket After Q2 Results Beat

THOMSON REUTERS
·
05 Feb

Bio-Techne Q2 2025 Adj EPS $0.42 Beats $0.39 Estimate, Sales $297.03M Beat $285.98M Estimate

Benzinga
·
05 Feb

BRIEF-Bio-Techne Q2 Adjusted EPS USD 0.42 Vs. IBES Estimate USD 0.39

Reuters
·
05 Feb

Bio-Techne Q2 Operating Expenses USD 146.467 Million

THOMSON REUTERS
·
05 Feb

Press Release: Bio-Techne Declares Dividend

Dow Jones
·
05 Feb

Bio-Techne Appoints DR. Amy E. Herr to Board of Directors

THOMSON REUTERS
·
04 Feb

Bio-Techne Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
04 Feb

Press Release: SIMPLY SOLVENTLESS ANNOUNCES OVER SUBSCRIPTION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING TO $6.0 MILLION & EXPECTED DELTA 9 BIO-TECH CLOSING DATE OF FEBRUARY 7, 2025

Dow Jones
·
03 Feb

Bio-Techne Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
31 Jan

TECH Gears Up to Report Q2 Earnings: Here's What to Expect

Zacks
·
30 Jan

Bio-Techne Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
29 Jan

Baird Adjusts Bio-Techne Price Target to $86 From $84, Maintains Outperform Rating

MT Newswires Live
·
27 Jan

Bio-Techne Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
24 Jan